📣 Big News from PurpleAI!
We’re proud to announce that our AI Aneurysm module has received KFDA clearance! This marks a major milestone—completing a large portion of our Medical Insight+ Suite and reinforcing our commitment to full-spectrum, AI-driven stroke diagnostic support solutions.
🧠 About Medical Insight+ Brain Aneurysm
The diagnostic support solution assists in the early detection of cerebral aneurysms on brain CTA scans. Early detection of cerebral aneurysms is crucial because unruptured aneurysms often have no symptoms until they rupture. Aneurysm rupture can lead to severe and often fatal cerebral hemorrhage (subarachnoid hemorrhage), with reported mortality rates of 40-50% and significant long-term disability in survivors.
🧩 Medical Insight+ Suite Overview
PurpleAI’s full KFDA-approved suite now includes: 🔹 Medical Insight+ Brain Hemorrhage – Intracranial hemorrhage (ICH) detection 🔹 Medical Insight+ Brain Infarct – Ischemic stroke identification 🔹 Medical Insight+ Brain Aneurysm – Intracranial aneurysm detection
📌 What’s Next?
AI Aneurysm is available now, with pilot implementations underway. As we expand globally, we’re excited to bring smarter, faster diagnostics to more hospitals and patients.
And we're moving beyond detection—into predictive, multimodal analytics that anticipate complications and empower earlier intervention.
#PurpleAI #FDA #AIClearance #Aneurysm #StrokeCare #MedicalAI #NeuroRadiology #HealthTech #Innovation